FPWR has once again partnered with COMBINEDBrain to collect blood and urine samples for our PWS & SYS biorepositories.
FPWR
Recent Posts
This study is on a voluntary pause while the company works to secure funding. Study Purpose Tesomet is a first-in-class triple monoamine re-uptake inhibitor / beta-1 blocker which is being studied as a possible treatment for hyperphagia in Prader-Willi syndrome.
Study Purpose Guanfacine Extended Release (GXR), is an FDA approved drug used to treat children and adolescents with hypertension and attention deficit hyperactivity disorder (ADHD).This will be the first study to evaluate the drug in patients with Prader Willi Syndrome.
Got Anxiety? Want to help pave the way for new medicines to treat anxiety in PWS? Levo Therapeutics and the Foundation for Prader-Willi Research are working to develop a new questionnaire for use in clinical studies of novel treatments for PWS. We want to know more about how anxiety is expressed in people with PWS.
Dr. Lawrence T. Reiter at the University of Tennessee Health Science Center in Memphis, TN is conducting a research study to determine if neurons can be grown from the dental pulp of individuals with various neurogenetic syndromes including chromosomal duplications and deletions of human chromosome 15q, including PWS. These neurons will be valuable tool in understanding the differences between PWS and non-PWS, as well as for testing potential therapeutics.
Ferring Pharmaceuticals concluded a Phase II trial in 2014. The goal of the study was to evaluate the safety and effectiveness of an intranasal oxytocin analogue in treating hyperphagia in children and young adults with Prader-Willi Syndrome. Participants were between the ages of 10-18, in nutritional phase 3, and with a genetic confirmation of PWS.
